MC
ONC

Martin Currie’s BeOne Medicines Ltd ONC Stock Holding History

Martin Currie’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3,100
Closed -$93K – 109
2016
Q2 		$93K Hold
3,100
– – 0.01% 100
2016
Q1 		$91K Buy
+3,100
New +$87.8K 0.01% 99

Other funds holding ONC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Martin Currie's ONC Position: Q3 2016 in Review

Martin Currie sold out of BeOne Medicines Ltd (ONC) in Q3 2016, closing a stake of 3,100 shares — an estimated $93K sold.

Martin Currie first reported a position in ONC in Q1 2016 and held it in 2 quarters. The position peaked at $93K in Q2 2016. 39 funds tracked by Wall St. Rank hold ONC as of Q3 2016.

  • Martin Currie reported no remaining BeOne Medicines Ltd position as of Q3 2016 after selling out during the quarter.
  • Martin Currie sold 3,100 BeOne Medicines Ltd shares in Q3 2016, an estimated $93K.
  • Martin Currie first reported a position in BeOne Medicines Ltd in Q1 2016 and held it in 2 quarters.
  • Martin Currie's BeOne Medicines Ltd position peaked at $93K in Q2 2016.
  • 39 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2016.

Based on Martin Currie's 13F filing for Q3 2016, filed 14 Nov 2016.